Ultrasound-guided transvaginal radiofrequency myolysis for symptomatic uterine myomas

Intrauterine adhesion after transvaginal ultrasound‐guided radiofrequency myolysis

“…Transvaginal ultrasound‐guided RF myolysis has been reported in the literature to be safe, eliminates symptoms and decreases myoma size. Long‐term complications are uncommon . To the best of our knowledge, this study describes the first reported case of IUA after transvaginal ultrasound‐guided RF myolysis.…”

“…and Jiang et al . reported several patients experienced successful conception and childbirth after transvaginally ultrasound‐guided RF myolysis procedure . Therefore, it is important to carefully select patients for RF myolysis, considering the number, size and location of the myoma, as well as the pregnancy plans of the patient.…”

“…Transvaginal ultrasound‐guided RF myolysis has been proven to reduce myoma symptoms and volume. Many studies have demonstrated the midterm and long‐term treatment effect of this procedure; however, few studies have reported adverse outcomes and most of the reported complications were minor events, such as pain, vaginal discharge and pelvic adhesion . However, concern has been expressed about uterine rupture during future pregnancies after this procedure .…”

“…Many studies have demonstrated the midterm and long-term treatment effect of this procedure; however, few studies have reported adverse outcomes and most of the reported complications were minor events, such as pain, vaginal discharge and pelvic adhesion. [1][2][3][4][5][6][7] However, concern has been expressed about uterine rupture during future pregnancies after this procedure. 8,9 Here, we suggest that intrauterine adhesion (IUA) may occur as a result of procedure-related changes in the endometrium.…”

Cytokine Profile in Complications of Hormone Therapy Administered for Uterine Fibroids

“…В работах последних лет доказана немаловажная роль дисфункции иммунной системы, дисбиотических нарушений и сексуально-трансмиссивных инфекций в пато-генезе ММ [3,9,13]. В настоящее время предложено множество различных вариантов органосохраняющего лече-ния ММ, включающего химиотерапию, консер-вативную миомэктомию с помощью гистероско-пии, лапароскопии и лапаротомии, эмболизацию маточных артерий, дистанционное разрушение опухоли фокусированным ультразвуком под кон-тролем МРТ [6,12,14,19,22,24]. Однако, несмо-тря на широкое внедрение высоких хирургиче-ских технологий при лечении ММ, вероятность рецидива заболевания в течение 5 лет составляет 45-55% [22,24].…”